On July 13, Ali Health fell 3.17% in regular trading, trading at HK$3.36 per share, with turnover of HK$176 million.

On the news front, the medical e-commerce sector came under broad selling pressure, with peer JD Health declining 1.23% and PA Good Doctor dropping 1.33%, dragging Ali Health lower through sector linkage. Additionally, UBS previously maintained a sell rating on Ali Health and cut its target price from HK$3.6 to HK$3.1, with FY2027-FY2029 earnings forecasts trimmed by 5%. The current stock price is now approaching that target, reflecting continued bearish sentiment. Southbound capital has cumulatively net sold approximately 128 million shares over the past 20 trading days, intensifying downward pressure on the stock.

For context, the company reported FY2026 revenue of RMB 34.255 billion, up 12.0% year-over-year, with net profit rising 35.2% to RMB 1.936 billion. The board also proposed a share buyback authorization of up to 10% of issued shares, though these positive fundamentals have yet to offset the prevailing negative analyst outlook.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)